Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $257.81M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 8.49M
Average 10.19M
Returns on capital
Allogene Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-65.3%
avg -27.1%
ROIC
-52.8%
avg -33.1%
ROA
-45.9%
avg -30.7%
Analysis
ROA is currently the strongest return metric at -45.9% versus its period average of -30.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David D. Chang | Co-Founder & Director | USD 1.14M | 66 | 5.15M | 2.11% |
Joshua A. Kazam | Co-Founder & Director | USD 1.14M | 49 | 0 | <0.01% |
Zachary J. Roberts | President, CEO & Director | USD 750.76K | 48 | — | — |
Arie S. Belldegrun | Co-Founder & Executive Chairman | USD 728.73K | 77 | — | — |
Geoffrey Parker | Executive Vice President & Chief Financial Officer | USD 707K | 61 | — | — |
Benjamin Beneski | Senior Vice President & Chief Technical Officer | — | 49 | — | — |
Earl Douglas | Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary | — | 63 | — | — |
Annie Yoshiyama | Senior VP of Finance, Corporate Controller & Principal Accounting Officer | — | 42 | 124.52K | 0.05% |
Christine Cassiano | Executive Vice President, Chief Corporate Affairs & Brand Strategy Officer | — | — | — | — |
Susan R. Lundeen | Chief People Officer | — | 60 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$667,852.95
Net Transaction Value
−$667,852.95
Net selling
Most Active
Beneski Benjamin Machinas
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 21, 26Oct 21, 2026 | Parker Geoffrey M. Direct | Sell | $48.7K$48,698.28 |
| Aug 21, 26Aug 21, 2026 | Douglas Earl Martin Direct | Sell | $63K$62,957.64 |
| Apr 21, 26Apr 21, 2026 | Yoshiyama Annie Direct | Sell | $22.1K$22,143.66 |
| Mar 31, 26Mar 31, 2026 | Beneski Benjamin Machinas Direct | Sell | $7.2K$7,167.50 |
| Mar 16, 26Mar 16, 2026 | Beneski Benjamin Machinas Direct | Sell | $11.9K$11,942.45 |
| Mar 16, 26Mar 16, 2026 | Chang David D Direct | Sell | $118K$117,974.61 |
| Mar 2, 26Mar 2, 2026 | Beneski Benjamin Machinas Direct | Sell | $18.5K$18,543.20 |
| Feb 2, 26Feb 2, 2026 | Beneski Benjamin Machinas Direct | Sell | $13.1K$13,059.77 |
| Feb 2, 26Feb 2, 2026 | Chang David D Direct | Sell | $171.5K$171,484.20 |
| Feb 2, 26Feb 2, 2026 | Parker Geoffrey M. Direct | Sell | $42.2K$42,241.76 |
1–10 of 14
Summary
Insiders reported 0 buys worth $0.00 and 14 sells worth $667,852.95 over the last 12 months. That adds up to net selling of $667,852.95. Beneski Benjamin Machinas was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Allogene Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ALLO's management, answered from reported figures.
Who manages ALLO?
Allogene Therapeutics, Inc. (ALLO) lists 10 active executives. The top listed executive is David D. Chang, Co-Founder & Director.
Are ALLO insiders buying or selling?
Recent insider activity shows net buying of $111.60M.
Continue the stock analysis
Jump to another research area for this company.